Regulation of LKB1/STRAD localization and function by E-cadherin - PubMed (original) (raw)
Regulation of LKB1/STRAD localization and function by E-cadherin
Michael Sebbagh et al. Curr Biol. 2009.
Abstract
LKB1 kinase is a tumor suppressor that is causally linked to Peutz-Jeghers syndrome. In complex with the pseudokinase STRAD and the scaffolding protein MO25, LKB1 phosphorylates and activates AMPK family kinases, which mediate many cellular processes. The prototypical family member AMPK regulates cell energy metabolism and epithelial apicobasal polarity. This latter event is also dependent on E-cadherin-mediated adherens junctions (AJs) at lateral borders. Strikingly, overexpression of LKB1/STRAD can also trigger establishment of epithelial polarity in the absence of cell-cell or cell-matrix contacts. However, the upstream factors that normally govern LKB1/STRAD function are unknown. Here we show by immunostaining and fluorescence resonance energy transfer that active LKB1/STRAD kinase complex colocalizes with E-cadherin at AJs. LKB1/STRAD localization and AMPK phosphorylation require E-cadherin-dependent maturation of AJs. However, LKB1/STRAD complex kinase activity is E-cadherin independent. These data suggest that in polarized epithelial cells, E-cadherin regulates AMPK phosphorylation by controlling the localization of the LKB1 complex. The LKB1 complex therefore appears to function downstream of E-cadherin in tumor suppression.
Figures
Figure 1. LKB1 localizes at adherens junction level in polarized epithelial cells
(A) Polarized Caco-2 stained for LKB1 (green) and E-cadherin (red). (B) xz projection of polarized Caco-2 cells stained for LKB1 (green) and villin (red) or (C) for LKB1 (green) and ZO-1 (red). (D) Polarized Caco-2 cells were fractionated as described in “experimental procedures” and analyzed for indicated proteins. Results are representative of two independent experiments. (E) MDCK clones stably knocked down for LKB1 (cl) by shRNA or control construct (shLuc) transiently transfected by either GFP alone or GFP-LKB1wt were analysed by Western blotting for indicated proteins. (F) AMPKp-172/total AMPK ratio (black bar) were determined and plotted with endogenous (endo, white bar) and exogenous (exo, grey bar) LKB1, all relative to control. Values are means ± S.D., (n=2). (G) Polarized MDCK shLuc and shLKB1 cl 14 were stained for LKB1 (green), E-cadherin (purple) and villin (red). Bars, 10µm.
Figure 2. STRAD localizes with LKB1 at adherens junction level
(A) Polarized MDCK shLuc or shLKB1 cl 14 cells were stained for LKB1 (green), E-cadherin (purple) and STRAD (red). (B) Polarized Caco-2 clone knocked down for LKB1 (cl A12) or not (shLuc) were fractionated as in figure 1. (C) Membranous shLKB1 cl A12/shLuc ratio for LKB1, STRADα, total or phosphorylated AMPK, normalized to E-cadherin. Values are means ± S.D., (n=3). (D) MDCK cells on fibronectin-coated coverslips were transiently transfected with YFP-STRADα (yellow) plus either CFP-Myr, wild type or SL26 CFP-LKB1 (blue). FRET was measured as described in “Experimental Procedures”. The asterisks mark an unidentified perinuclear compartment. (E) Projections of FRET images from CFP-LKB1-WT and YFP-STRADα. FRET intensity is displayed on a pseudocolor scale in arbitrary units. Bars, 10µm.
Figure 3. E-cadherin is required to localize LKB1 at adherens junctions level
(A) MDCK cells expressing control (shLuc) or E-cadherin (shE-cad) shRNA vectors were analysed by Western blot for the indicating proteins. (B) Cells were stained for LKB1 (green) and E-cadherin (red). Bars, 10µm. (C) MDCK cells described in A were fractionated as described in figure 1, (D) Ratio of membranous shE-cad/shLuc of LKB1, STRADα, total or phosphorylated AMPK, normalized to integrin. Values are means ± S.D., (n=2).
Figure 4. E-cadherin knockdown decrease AMPK activation
(A) MDCK cells were transiently transfected with control (shLuc) or shRNA targetting canine E-cadherin (shE-cad). Cells were extracted at indicated times and analyzed by Western blot for indicated proteins. (B) T172 AMPK phosphorylation and E-cadherin levels were quantified and normalized to total AMPK. Values are percent relative to levels in shLuc or shE-cad cells at 24h (means ± S.D. n=3). pAMPK: white bars; E-cadherin: black bars. (C) The same lysates were immunoprecipitated with anti-LKB1 and kinase activity analyzed in vitro (IVK). (D) Kinase activity was quantified and normalized to total immunoprecipitated LKB1, plotted as described in B (means ± S.D. n=4). Control (shLuc) and E-cadherin-depleted MDCK cells were transiently transfected or not with wild type human E-cadherin (pcDNAhE-cad). After 24h cells, were extracted and treated as in A and C (E, F respectively**)** and quantified (G). T172 AMPK phosphorylation in cells (white bar), LKB1 IP kinase activity (TK) (black bar), control shLuc cells mock transfected was used as reference (means ± S.D. n=3). (H) Stable control (shLuc) and LKB1 depleted (shLKB cl14) MDCK cells were transiently transfected or not with shRNA targeting canine E-cadherin (shE-cad). After 72h, cells were lysed and analyzed by Western blotting with the specified antibodies (n=2).
Similar articles
- Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade.
Hawley SA, Boudeau J, Reid JL, Mustard KJ, Udd L, Mäkelä TP, Alessi DR, Hardie DG. Hawley SA, et al. J Biol. 2003;2(4):28. doi: 10.1186/1475-4924-2-28. Epub 2003 Sep 24. J Biol. 2003. PMID: 14511394 Free PMC article. - Analysis of the LKB1-STRAD-MO25 complex.
Boudeau J, Scott JW, Resta N, Deak M, Kieloch A, Komander D, Hardie DG, Prescott AR, van Aalten DM, Alessi DR. Boudeau J, et al. J Cell Sci. 2004 Dec 15;117(Pt 26):6365-75. doi: 10.1242/jcs.01571. Epub 2004 Nov 23. J Cell Sci. 2004. PMID: 15561763 - Effects of 3-phosphoglycerate and other metabolites on the activation of AMP-activated protein kinase by LKB1-STRAD-MO25.
Ellingson WJ, Chesser DG, Winder WW. Ellingson WJ, et al. Am J Physiol Endocrinol Metab. 2007 Feb;292(2):E400-7. doi: 10.1152/ajpendo.00322.2006. Epub 2006 Sep 19. Am J Physiol Endocrinol Metab. 2007. PMID: 16985256 - LKB1 biology: assessing the therapeutic relevancy of LKB1 inhibitors.
Trelford CB, Shepherd TG. Trelford CB, et al. Cell Commun Signal. 2024 Jun 6;22(1):310. doi: 10.1186/s12964-024-01689-5. Cell Commun Signal. 2024. PMID: 38844908 Free PMC article. Review. - LKB1-dependent signaling pathways.
Alessi DR, Sakamoto K, Bayascas JR. Alessi DR, et al. Annu Rev Biochem. 2006;75:137-63. doi: 10.1146/annurev.biochem.75.103004.142702. Annu Rev Biochem. 2006. PMID: 16756488 Review.
Cited by
- Membrane-binding and activation of LKB1 by phosphatidic acid is essential for development and tumour suppression.
Dogliotti G, Kullmann L, Dhumale P, Thiele C, Panichkina O, Mendl G, Houben R, Haferkamp S, Püschel AW, Krahn MP. Dogliotti G, et al. Nat Commun. 2017 Jun 26;8:15747. doi: 10.1038/ncomms15747. Nat Commun. 2017. PMID: 28649994 Free PMC article. - Folliculin haploinsufficiency causes cellular dysfunction of pleural mesothelial cells.
Okamoto S, Ebana H, Kurihara M, Mitani K, Kobayashi E, Hayashi T, Sekimoto Y, Nishino K, Otsuji M, Kumasaka T, Takahashi K, Seyama K. Okamoto S, et al. Sci Rep. 2021 May 24;11(1):10814. doi: 10.1038/s41598-021-90184-9. Sci Rep. 2021. PMID: 34031471 Free PMC article. - Development of a Genetically Engineered Mouse Model Recapitulating LKB1 and PTEN Deficiency in Gastric Cancer Pathogenesis.
Fang KT, Hung H, Lau NYS, Chi JH, Wu DC, Cheng KH. Fang KT, et al. Cancers (Basel). 2023 Dec 18;15(24):5893. doi: 10.3390/cancers15245893. Cancers (Basel). 2023. PMID: 38136437 Free PMC article. - A lateral belt of cortical LGN and NuMA guides mitotic spindle movements and planar division in neuroepithelial cells.
Peyre E, Jaouen F, Saadaoui M, Haren L, Merdes A, Durbec P, Morin X. Peyre E, et al. J Cell Biol. 2011 Apr 4;193(1):141-54. doi: 10.1083/jcb.201101039. Epub 2011 Mar 28. J Cell Biol. 2011. PMID: 21444683 Free PMC article. - The LKB1-AMPK pathway: metabolism and growth control in tumour suppression.
Shackelford DB, Shaw RJ. Shackelford DB, et al. Nat Rev Cancer. 2009 Aug;9(8):563-75. doi: 10.1038/nrc2676. Nat Rev Cancer. 2009. PMID: 19629071 Free PMC article.
References
- Sanchez-Cespedes M. A role for LKB1 gene in human cancer beyond the Peutz-Jeghers syndrome. Oncogene. 2007;26:7825–7832. - PubMed
- Luo Z, Saha AK, Xiang X, Ruderman NB. AMPK, the metabolic syndrome and cancer. Trends Pharmacol Sci. 2005;26:69–76. - PubMed
- Lee JH, Koh H, Kim M, Kim Y, Lee SY, Karess RE, Lee SH, Shong M, Kim JM, Kim J, Chung J. Energy-dependent regulation of cell structure by AMP-activated protein kinase. Nature. 2007;447:1017–1020. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases